Iceland Could Identify Almost Every Woman at High Risk of Breast Cancer. It Doesn't

A single BRCA2 founder mutation accounts for most hereditary breast cancer in Iceland, and the country has the genomic data to find carriers. Why it holds back is one of the sharpest ethical questions in genetics — the right not to know.

Iceland is a population geneticist's ideal: small, well documented, genealogically recorded for centuries, and extensively sequenced. Researchers there published whole-genome sequences for 2,636 Icelanders and used them to impute genotypes across a large fraction of the population (Gudbjartsson et al., Nature Genetics, 2015, PMID: 25807286).

One consequence of that work is uncomfortable. In a population with a strong founder effect, a single inherited variant can account for most of a disease's hereditary burden — and in Iceland, a specific BRCA2 founder mutation does exactly that for hereditary breast and ovarian cancer.

Which means the data to find carriers, in a country of under 400,000 people, substantially exists.

Nobody is being told.

Why not

Because they did not ask.

Genetic data in research studies is gathered under consent for research. Using it to contact people about a personal cancer risk they never enquired about is a different act, governed by different rules, and it collides with a principle written into European and UNESCO frameworks: the right not to know.

That right sounds strange until you sit with it. A person may reasonably prefer not to carry knowledge they cannot act on comfortably, or that would reshape how they see their children, or that arrives without the counselling and follow-up that should accompany it. Autonomy includes the freedom to decline information.

Set against that: BRCA2 carriers face substantially elevated lifetime risk, and surveillance and risk-reducing surgery meaningfully change outcomes. Withholding a finding that could prevent a death is not a neutral act either.

Both positions are serious. That is what makes it a genuine dilemma rather than an easy one.

Penetrance is not fixed

There is a further complication that cuts against fatalism about any single variant.

A population-based study of Icelandic BRCA2 carriers tracked breast cancer risk across the twentieth century and found it changed over time (Tryggvadóttir et al., Journal of the National Cancer Institute, 2006, PMID: 16418514).

The same mutation. Different decades. Different risk.

Whatever moved — reproductive patterns, diet, body composition, environmental exposures — the penetrance of a well-characterised pathogenic variant is not a constant of nature. A carrier is not reading a fixed sentence, and any counselling that presents lifetime risk as a single unchanging number oversimplifies.

What this means for consumer testing

Direct-to-consumer genetics inverts the Icelandic situation. Instead of institutions holding information about people who did not ask, individuals go looking on their own.

That makes the right not to know something you exercise for yourself — but it also means results can arrive without a clinician present, and often without the specific variant that matters most for your background being on the chip at all. Founder mutations like Iceland's are frequently absent from consumer arrays.

Two practical consequences follow. A reassuring consumer result is not a clinical all-clear. And if your family history points toward hereditary cancer, the appropriate route is clinical genetic testing with counselling — not an app, and not this article.

The question worth sitting with

Iceland's dilemma is arriving everywhere, more quietly, as biobanks grow. Someone, somewhere, is holding a fact about your body that you have not asked for.

Whether they should tell you is not a scientific question. The science is settled enough. What remains is a decision about what you are owed — and whether you get to say no.